AC Immune wins FDA fast-track status for Parkinson’s immunotherapy ACI-7104

AC Immune won U.S. FDA Fast Track designation for ACI-7104 in early Parkinson’s disease; the agency also cleared the program’s IND.

A $4 million research grant from the Vijay and Marie Goradia Charitable Foundation will support a two-year extension of the Phase 2 VacSYn trial.

Interim Phase 2 data at 76 weeks showed no clinically relevant safety issues; immunogenicity hit targets with a 100% responder rate.